Clinical trial · Interventional
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)
A Multicenter Trial to Measure Early Patterns of Change in [18F]-Fluorodeoxyglucose Uptake by PET/CT in Relapsed Ovarian Cancer Patients
NCT00959582CI-TRIAL-00016680completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will characterize FDG-PET (18F-Fluorodeoxyglucose-Positron Emission Tomography) as an early response marker in recurrent, platinum-sensitive ovarian cancer treated with platinum-based therapy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Cancer | Malignant Fallopian Tube Neoplasm | ALIAS | 0.90 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Primary Peritoneal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Comparator: 18-F-FDG PET/CT and Volumetric CT | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- 18-F-FDG PET/CT imaging
- interventionNames
- Procedure: Comparator: 18-F-FDG PET/CT and Volumetric CT
Primary outcomes (2)
- measure
- Proportion of patients with metabolic non-response assessed by FDG-PET standardized uptake value (SUV) 3 weeks and 6 weeks after starting platinum-based therapy
- timeFrame
- Baseline, Week 3, Week 6
- measure
- Progression free proportion
- timeFrame
- 40 Weeks
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Patient has ovarian, primary peritoneal, or fallopian tube cancer * Patient has first or subsequent relapse * Patient has had at least on prior platinum-based treatment for ovarian cancer * Patient is scheduled to receive treatment with carboplatin or cisplatin monotherapy or combination where one of the drugs is a platinum * Patient is not pregnant Exclusion Criteria: * Patient has had abdominal surgery within the last 6 weeks * Patient has life expectancy \< 6 months * Patient has had radiotherapy to the abdomen or pelvis within the last 6 months * Patient has poorly controlled diabetes
References
Publications (0)
Data not yet available
No reference posted for this study.